NCT02031419 2024-01-18
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
Celgene
Phase 1 Terminated
Clinical Trials
3 trialsNCT01732861 2019-12-20
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma
Celgene
Phase 1 Completed
NCT01744626 2016-04-19
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Celgene Corporation
Phase 1 Completed